Table 1.
Baseline characteristics of study population.
| Asthma n = 29 |
Controls n = 29 |
p-Value | |
|---|---|---|---|
| Sex male, (%) | 18 (62%) | 16 (55.2%) | 0.182 |
| Age (years), mean (±SD) | 8.9 ± 4.7 | 10.9 ± 5.7 | 0.071 |
| Comorbidities | - | ||
| AD n (%) | 12 (41.4%) | - | |
| FA n (%) | 6 (20.7%) | - | |
| AR n (%) | 14 (48.3%) | - | |
| Laboratory data | |||
| Ig E IU/mL mean (±SD) | 582.7 ± 188.4 | 103.13 ± 16.7 | 0.0001 |
| WBC count (1000/mm3) | 8.9 | 7.4 | 0.21 |
| Neutrophil count | 62% | 58.4% | 0.59 |
| Eosinophil count | 8.4% | 3.2% | 0.0001 |
| CRP mg/dL mean (±SD) | 0.95 (±0.84) | 0.65 (±0.41) | 0.44 |
| Asthma medication | |||
| Inhaled SABA frequency n (%) | |||
| None | 2 (6.9%) | - | |
| <1/month | 20 (68.9%) | - | |
| ≥1/month | 7 (24.1%) | - | |
| Asthma severity n (%) | |||
| Intermittent | 8 (27.5%) | - | |
| Mild persistent | 9 (31%) | - | |
| Moderate or severe persistent | 12 (41.4%) | - | |
| Inhaled corticosteroid grade | |||
| None | 4 (13.8) | - | |
| Low dose | 13 (44.8%) | - | |
| Medium or high dose | 12 (41.4%) | - |
AD, atopic dermatitis; FA, food allergy; AR, allergic rhinitis; WBC, white blood cell; SABA, short-acting beta agonist; CRP, C reactive protein.